CFDA approves production of the first Sabin IPV

China Food and Drug Administration (CFDA) has approved the production of the first inactivated poliomyelitis vaccine made from inactivated Sabin strains (Sabin IPV). It was researched and developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences.

Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the poliovirus. It is a virus-transmitted disease that can lead to paralysis and limb deformation. Two effective vaccines currently exist, the inactivated, or “killed”, (Salk) vaccine and the attenuated, or “live”, (Sabin) vaccine.

The global end to polio transmission would have been inconceivable without both the “killed” (Salk) and “live” (Sabin) vaccines. Neither Jonas Salk nor Albert Sabin patented their vaccines but they donated the rights as gifts to humanity.

The vaccine is used to prevent children from infecting the poliovirus through injection. The launch of the Sabin IPV will play a critical role for the eradication of poliomyelitis in China by relying on local manufacturing capabilities to meet the demand of producing several million doses annually.

Click here for the press release by CFDA.

Leave a Reply

Your email address will not be published. Required fields are marked *